OBJECTIVE: We evaluated the expression of human trophoblast cell-surface marker (Trop-2) and the potential of hRS7, a humanized monoclonal anti-Trop-2 antibody, against treatment-refractory cervical cancer. STUDY DESIGN: Trop-2 expression was evaluated by immunohistochemistry, real-time polymerase chain reaction, and flow cytometry. Sensitivity to hRS7 antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity was tested in 5-hour chromium release assays. The effect of interleukin (IL)-2 on hRS7 ADCC was also investigated. RESULTS: Membrane Trop-2 expression was observed in 8 of 8 (100%) of the cancer samples tested by immunohistochemistry, but not in normal cervix. High messenger RNA expression by real-time polymerase chain reaction and high Trop-2 surface expression by flow cytometry were detected in 80% of cervical cancers (4 of 5 cell lines). Although these tumors were resistant to natural killer cell-dependent cytotoxicity in vitro (mean killing, 6.0%), Trop-2-positive cell lines showed high sensitivity to hRS7 ADCC (range of killing, 30.6-73.2%). Incubation with IL-2 further increased the level of cytotoxicity against Trop-2-positive tumors. CONCLUSION: hRS7 may represent a novel treatment option for patients with cervical cancer refractory to conventional treatment modalities.
OBJECTIVE: We evaluated the expression of human trophoblast cell-surface marker (Trop-2) and the potential of hRS7, a humanized monoclonal anti-Trop-2 antibody, against treatment-refractory cervical cancer. STUDY DESIGN:Trop-2 expression was evaluated by immunohistochemistry, real-time polymerase chain reaction, and flow cytometry. Sensitivity to hRS7 antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity was tested in 5-hour chromium release assays. The effect of interleukin (IL)-2 on hRS7 ADCC was also investigated. RESULTS: Membrane Trop-2 expression was observed in 8 of 8 (100%) of the cancer samples tested by immunohistochemistry, but not in normal cervix. High messenger RNA expression by real-time polymerase chain reaction and high Trop-2 surface expression by flow cytometry were detected in 80% of cervical cancers (4 of 5 cell lines). Although these tumors were resistant to natural killer cell-dependent cytotoxicity in vitro (mean killing, 6.0%), Trop-2-positive cell lines showed high sensitivity to hRS7 ADCC (range of killing, 30.6-73.2%). Incubation with IL-2 further increased the level of cytotoxicity against Trop-2-positive tumors. CONCLUSION: hRS7 may represent a novel treatment option for patients with cervical cancer refractory to conventional treatment modalities.
Authors: R Stein; S V Govindan; M J Mattes; L B Shih; G L Griffiths; H J Hansen; D M Goldenberg Journal: Clin Cancer Res Date: 1999-10 Impact factor: 12.531
Authors: L Zhang; W Zhou; V E Velculescu; S E Kern; R H Hruban; S R Hamilton; B Vogelstein; K W Kinzler Journal: Science Date: 1997-05-23 Impact factor: 47.728
Authors: F Landoni; A Maneo; A Colombo; F Placa; R Milani; P Perego; G Favini; L Ferri; C Mangioni Journal: Lancet Date: 1997-08-23 Impact factor: 79.321
Authors: Joyce Varughese; Emiliano Cocco; Stefania Bellone; Maria de Leon; Marta Bellone; Paola Todeschini; Peter E Schwartz; Thomas J Rutherford; Sergio Pecorelli; Alessandro D Santin Journal: Cancer Date: 2011-01-18 Impact factor: 6.860
Authors: M A Caligiuri; C Murray; M J Robertson; E Wang; K Cochran; C Cameron; P Schow; M E Ross; T R Klumpp; R J Soiffer Journal: J Clin Invest Date: 1993-01 Impact factor: 14.808
Authors: S Miotti; S Canevari; S Ménard; D Mezzanzanica; G Porro; S M Pupa; M Regazzoni; E Tagliabue; M I Colnaghi Journal: Int J Cancer Date: 1987-03-15 Impact factor: 7.396
Authors: Hyungsoon Im; Cesar M Castro; Huilin Shao; Monty Liong; Jun Song; Divya Pathania; Lioubov Fexon; Changwook Min; Maria Avila-Wallace; Omar Zurkiya; Junsung Rho; Brady Magaoay; Rosemary H Tambouret; Misha Pivovarov; Ralph Weissleder; Hakho Lee Journal: Proc Natl Acad Sci U S A Date: 2015-04-13 Impact factor: 11.205